Anti-AT1R and anti-ETAR autoantibodies could provide novel targets for therapeutic intervention in the treatment of SSc. PubMed, Arthritis Res Ther, 2014 Jan 28;16(1):R29. (Also see: Scleroderma Autoantibodies)
This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.